A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Exclusion Criteria

• •1. Received treatment with other experimental therapies within the last 30 days prior to the first dose
• •2. Requiring mechanical ventilation, other than positive air pressure support primarily for mitigation of sleep apnea.
• •3. Have a life expectancy of less than one year
• •4. Diagnosis of atypical NAD (ANAD)
• •5. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to return for visits as scheduled